Coya Therapeutics (COYA) Current Assets (2021 - 2026)
Coya Therapeutics (COYA) posted Current Assets of $53.3 million for Q1 2026, up 6.66% sequentially from $49.9 million in Q4 2025, and up 38.8% YoY from $38.4 million in Q1 2025.
Coya Therapeutics (COYA) Current Assets (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Current Assets for 6 years, with the latest figure at $53.3 million in Q1 2026.
- Quarterly Current Assets rose 38.8% year-over-year to $53.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.3 million (up 38.8% YoY) and the FY2025 annual result came in at $49.9 million, up 12.71% from the prior year.
- Current Assets rose to $53.3 million in Q1 2026 per COYA's latest filing, from $49.9 million in the prior quarter.
- Over five years, Current Assets peaked at $53.3 million in Q1 2026 and troughed at $7.2 million in Q4 2022.
- A 5-year average of $32.6 million and a median of $36.4 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets jumped 473.37% in 2023, then retreated 16.19% in 2025.
- Over 5 years, Current Assets stood at $7.2 million in 2022, then surged by 473.37% to $41.2 million in 2023, then gained by 7.55% to $44.3 million in 2024, then rose by 12.71% to $49.9 million in 2025, then advanced by 6.66% to $53.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $53.3 million, $49.9 million, and $32.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | 47.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.06 Mn |
| Mar 31, 2026 | 53.26 Mn |
| Dec 31, 2025 | 49.94 Mn |
| Sep 30, 2025 | 32.02 Mn |
| Jun 30, 2025 | 33.43 Mn |
| Mar 31, 2025 | 38.37 Mn |
| Dec 31, 2024 | 44.31 Mn |
| Sep 30, 2024 | 35.51 Mn |
| Jun 30, 2024 | 39.89 Mn |
| Mar 31, 2024 | 37.33 Mn |
| Dec 31, 2023 | 41.20 Mn |
| Sep 30, 2023 | 11.82 Mn |
| Jun 30, 2023 | 14.39 Mn |
| Mar 31, 2023 | 17.33 Mn |
| Dec 31, 2022 | 7.18 Mn |
| Dec 31, 2021 | 4.58 Mn |